Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review

Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review

Abstract In recent years, GLP-1 receptor agonists (GLP-1RA), and SGLT-2 inhibitors (SGLT-2i) have become available, which have become valuable additions to therapy for type 2 diabetes as they are associated with low risk for hypoglycemia and cardiovascular benefits. Indeed, SGLT-2i have emerged as a...

Full description

Bibliographic Details
Main Authors: Cristina Panico, Benedetta Bonora, Antonella Camera, Nino Cristiano Chilelli, Giuliana Da Prato, Giuseppe Favacchio, Valeria Grancini, Veronica Resi, Maurizio Rondinelli, Emanuela Zarra, Basilio Pintaudi
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2 inhibitors
Type 2 diabetes
Cardiovascular
Mechanism of action
Pathophysiology
Heart failure
Online Access:https://doi.org/10.1186/s12933-023-01855-y

Internet

https://doi.org/10.1186/s12933-023-01855-y

Similar Items